AMR – What is the Alternative
Note: This description is sourced from the original post. We recommend reading the full post on the event site.
Antimicrobial resistance (AMR) poses a critical challenge to global health, requiring urgent action to raise awareness and drive collaboration between researchers, industry leaders and policymakers.
Addressing AMR is essential to safeguarding the effectiveness of modern medicine and ensuring sustainable healthcare solutions.
This meeting will explore the societal importance of combating AMR and discuss alternative solutions, including the role of the gut microbiome in resistance development, the potential of entirely new classes of antibacterials and rapid diagnostic tools to improve treatment decisions.
We will also examine how microbiome research can inspire new approaches to bacterial defense mechanisms, the importance of responsible antibiotic use in agriculture and ongoing global initiatives to combat AMR.
Join the MVA R&D Network to gain insights from leading researchers and industry experts and engage with key stakeholders dedicated to tackling one of the most pressing healthcare challenges of our time.
We look forward to welcoming you to an insightful and engaging discussion on AMR and the search for alternatives.
Kristine Koppelhus will moderate the event, bringing together key stakeholders to accelerate action against antimicrobial resistance. With her expertise in moderation and facilitation, Kristine ensures dynamic and insightful discussions that connect academia, industry and key stakeholders.
Date: Thursday 24th April 2025
Time: 14:00 – 18:00
Venue: Malmö University, Niagara, Hörsal B2, Nordenskiöldsgatan 1, Malmö, Sweden
(5 min. walk from Malmö C station)
Program:
| 14.00 | Registration and networking |
| 14:30 | Welcome Anette Steenberg, CEO, Medicon Valley Alliance |
| 14:35 | Introduction Kristine Koppelhus, Medicon Valley Alliance |
| 14:50 | Antimicrobial Resistance and Plasmid Diversity in the Early Life Gut Microbiome Søren Johannes Sørensen, Professor, University of Copenhagen |
| 15:10 | A completely new class of antibacterials – Is the timing right? Markus Thor, CEO, Quretech |
| 15:30 | Innovative Rapid Test for Urinary Tract Infections: A High-Impact Solution to Combat AMR Line Vigga Kristensen CEO and Winnie E. Svendsen CTO, Uvigga |
| 16:00 | Coffee break |
| 16:30 | Utilizing global microbiome datasets to harness the power of bacterial offensive and defensive inventions Patrick Munk, Associate Professor, DTU National Food Institute |
| 16:50 | The Potential of Probiotics as an Alternative to Systemic Antibiotics in Dentistry Jakob Axelsson, Scientific Affairs and Research Manager, BioGaia |
| 17:10 | Antibiotic use in pigs – How to reduce it? John Haugegaard, Den Danske Dyrlægeforening |
| 17:40 | Networking and light snack |
| 18:00 | End of Meeting |
